Oncotelic reports positive Phase 2 COVID-19 data: 3X survival benefit for critical patients

Oncotelic Therapeutics, Inc.

Safety endpoints met; OT-101 was safe in severe/critical COVID-19 patients.
End-of-treatment mortality: 4.5% OT-101 vs 20% placebo.
Viral load knockdown >96% in 89% of OT-101 patients vs 67% placebo.
Overall survival for critical patients: 14 days OT-101 vs 4 days placebo (p<0.0166).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.